What if there was a way to substantially reduce high blood pressure for patients who have tried everything? Renal denervation is a hot topic, and ReCor Medical offers a unique ultrasound approach to enhance this exciting therapy…
OneMedRadio spoke with Clinova, a British pharmaceutical company focused on developing, manufacturing and marketing consumer healthcare products and medical device, has a rare global presence in multiple emerging markets, while also securing a significant market presence in Europe.
The first start-up by Bob Ward—The Polymer Technology Group (PTG)—earned a 555X return for investors upon its sale in 2008 to DSM, the global life sciences and materials company. Now, Bob Ward’s swinging away at another potential homerun: ExThera Medical, a Berkeley, California-based company, with its scientific origins at the Karolinska Institute in Stockholm, Sweden.
In the US and EU, HF is one of the most frequent diagnoses, and accounts for 7.5 million hospital days per year. Three to five percent of patients die despite hospitalization, half go home unimproved, 25% are readmitted within 30 days, and 30% die in six months.
DBV Technologies, whose shares are traded on segment C of Euronext Paris (Ticker: DBV), believes that its VIASKIN® platform is a game-changer, notably for children and adults who suffer from potentially lethal food allergies.
Acton, Mass.-based Cognoptix (formerly Neuroptix) has developed an entirely novel, early-stage diagnostic for Alzheimer’s disease (AD) to allow treatment before significant neuronal loss and irreversible brain damage occurs.
Young’s experience in both sectors makes him a unique voice in the osmosis of venture capital between mobile technology and life sciences. Young will participate in a panel dedicated to the subject at the 6th Annual OneMedForum in San Francisco, January 7-9. OneMedRadio spoke with Jack Young about investing in this sector, and the points of significant unmet medical need which represent the most promising opportunities.
OneMedPlace announced today that Peter Neupert of Health Evolution Partners and Jack Young of Qualcomm Ventures will participate in programming for the 6th Annual OneMedForum, January 7-9, 2013, in San Francisco. The two experts will take part in a panel dedicated to ‘Digital and Connected Health,’ an emerging sector with significant and diverse investment opportunities.
Last week, OneMedRadio spoke with Immune Pharmaceuticals founder and CEO Dr. Daniel Teper and Epicept Corporation President and CEO Robert Cook, to discuss the merger and the clinical focus of the merged company going forward.
Atossa Genetics [Nasdaq: ATOS] is a healthcare company focused on the development and marketing of novel cellular and molecular diagnostic risk assessment products for breast cancer through the detection of precursors to breast cancer.
Copyright © 2024 | WordPress Theme by MH Themes